An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19몰누피라비르 사용에 대한 업데이트된 실제 지침 및 COVID-19 치료를 위한 긴급 사용 승인을 받은 약제와의 비교Clinical Trial Published on 2022-02-012022-09-11 Journal: Diabetes & metabolic syndrome [Category] COVID19(2023년), SARS, 변종, 비임상, 신약개발, 임상, 치료법, 치료제, [키워드] 95% CI antiviral drug appear Bamlanivimab–etesevimab breath Casirivimab–imdevimab confidence interval Course COVID-19 COVID-19 patient database death effective Emergency use authorization EUA Google Scholar Hospital admission Hospitalization increased risk India medRxiv molnupiravir Nirmatrelvir Nirmatrelvir-ritonavir number onset of symptoms P-value patients with COVID-19 people with COVID-19 phase 3 study Prevent reduction in Relative risk Remdesivir reported risk risk difference risk reduction Ritonavir Safe SARS-CoV-2 searched severity Side effects Sotrovimab systematic review treat Treatment USA with COVID-19 [DOI] 10.1016/j.dsx.2022.102396 PMC 바로가기 [Article Type] Clinical Trial
Model-based cost-effectiveness analysis of oral antivirals against SARS-CoV-2 in Korea국내 SARS-CoV-2에 대한 경구용 항바이러스제의 모델 기반 비용 효율성 분석Article Published on 2022-01-012022-09-11 Journal: Epidemiology and Health [Category] SARS, 치료제, [키워드] Admission Adult patients Adults Analysis Antiviral antiviral agent Antiviral agents calculated Care coronavirus disease Coronavirus disease 2019 Cost-effectiveness analysis country COVID-19 COVID-19 patient Efficacy Elderly patient elderly patients Emergency use group health system Hospital admission Hospitalization ICU less medical system Mild-to-moderate molnupiravir Nirmatrelvir Patient patients predicted reduce reducing Ritonavir SARS-CoV-2 Severe case severe COVID-19 Severe patient standard care symptomatic Treatment underlying disease underlying diseases [DOI] 10.4178/epih.e2022034 PMC 바로가기 [Article Type] Article
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients사설: 입원하지 않은 환자의 SARS-CoV-2 감염에 대한 경구용 항바이러스제 치료 현황Editorial Published on 2022-01-012022-09-11 Journal: Medical science monitor : international medical jo [Category] SARS, 변종, 신약개발, 진단, 치료제, [키워드] administration antiviral drug antiviral drug treatment antiviral drugs approval approved bamlanivimab can be used Casirivimab children Community community setting costly COVID-19 current drug drug treatments early stage early stages editorial effective Emergency use authorization etesevimab EUA FDA healthcare facility Healthcare Products Regulatory Agency Hospitalization Imdevimab increased risk intravenous Intravenous administration Medicine Medicines MHRA Mild Moderate COVID-19 molnupiravir neutralizing monoclonal antibodies Nirmatrelvir oral Paxlovid positive priority product progression Regulatory Remdesivir Ritonavir SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 test SARS-CoV-2 virus severe COVID-19 status the SARS-CoV-2 virus therapeutic Treatment variants of concern [DOI] 10.12659/MSM.935952 PMC 바로가기 [Article Type] Editorial